FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963696315> ?p ?o ?g. }

• W1963696315 endingPage "664" @default.
• W1963696315 startingPage "657" @default.
• W1963696315 abstract "Type 2 diabetes is characterized by impaired β-cell function associated with progressive reduction of insulin secretion and β-cell mass. Evidently, there is an unmet need for treatments with greater sustainability in β-cell protection and antidiabetic efficacy. Through an insulin and β cell-independent mechanism, empagliflozin, a specific sodium glucose cotransporter type 2 (SGLT-2) inhibitor, may potentially provide longer efficacy. This study compared the antidiabetic durability of empagliflozin treatment (10 mg/kg p.o.) against glibenclamide (3 mg/kg p.o.) and liraglutide (0.2 mg/kg s.c.) on deficient glucose homeostasis and β-cell function in Zucker diabetic fatty (ZDF) rats. Empagliflozin and liraglutide led to marked improvements in fed glucose and hemoglobin A1c levels, as well as impeding a progressive decline in insulin levels. In contrast, glibenclamide was ineffective. Whereas the effects of liraglutide were less pronounced at week 8 of treatment compared with week 4, those of empagliflozin remained stable throughout the study period. Similarly, empagliflozin improved glucose tolerance and preserved insulin secretion after both 4 and 8 weeks of treatment. These effects were reflected by less reduction in β-cell mass with empagliflozin or liraglutide at week 4, whereas only empagliflozin showed β-cell sparing effects also at week 8. Although this study cannot be used to dissociate the absolute antidiabetic efficacy among the different mechanisms of drug action, the study demonstrates that empagliflozin exerts a more sustained improvement of glucose homeostasis and β-cell protection in the ZDF rat. In comparison with other type 2 diabetic treatments, SGLT-2 inhibitors may through insulin-independent pathways thus enhance durability of β-cell protection and antidiabetic efficacy." @default.
• W1963696315 created "2016-06-24" @default.
• W1963696315 creator A5001683046 @default.
• W1963696315 creator A5005755753 @default.
• W1963696315 creator A5006271095 @default.
• W1963696315 creator A5023246606 @default.
• W1963696315 creator A5073470602 @default.
• W1963696315 creator A5075602116 @default.
• W1963696315 creator A5076901585 @default.
• W1963696315 creator A5088582143 @default.
• W1963696315 date "2014-07-03" @default.
• W1963696315 modified "2023-09-27" @default.
• W1963696315 title "The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves <i>β</i>-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat" @default.
• W1963696315 cites W1598254642 @default.
• W1963696315 cites W1805517524 @default.
• W1963696315 cites W1971654760 @default.
• W1963696315 cites W1988031087 @default.
• W1963696315 cites W1989035610 @default.
• W1963696315 cites W1992267362 @default.
• W1963696315 cites W1996143753 @default.
• W1963696315 cites W2000845410 @default.
• W1963696315 cites W2013389100 @default.
• W1963696315 cites W2014577469 @default.
• W1963696315 cites W2021988691 @default.
• W1963696315 cites W2038961236 @default.
• W1963696315 cites W2038961968 @default.
• W1963696315 cites W2040687831 @default.
• W1963696315 cites W2054866483 @default.
• W1963696315 cites W2059673187 @default.
• W1963696315 cites W2068405048 @default.
• W1963696315 cites W2075224373 @default.
• W1963696315 cites W2080420487 @default.
• W1963696315 cites W2080449229 @default.
• W1963696315 cites W2089259629 @default.
• W1963696315 cites W2089273903 @default.
• W1963696315 cites W2105382539 @default.
• W1963696315 cites W2106036385 @default.
• W1963696315 cites W2117346812 @default.
• W1963696315 cites W2127588320 @default.
• W1963696315 cites W2135880911 @default.
• W1963696315 cites W2148958160 @default.
• W1963696315 cites W2151846672 @default.
• W1963696315 cites W2155287847 @default.
• W1963696315 cites W2160474387 @default.
• W1963696315 cites W2165956693 @default.
• W1963696315 doi "https://doi.org/10.1124/jpet.114.213454" @default.
• W1963696315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24993361" @default.
• W1963696315 hasPublicationYear "2014" @default.
• W1963696315 type Work @default.
• W1963696315 sameAs 1963696315 @default.
• W1963696315 citedByCount "51" @default.
• W1963696315 countsByYear W19636963152014 @default.
• W1963696315 countsByYear W19636963152015 @default.
• W1963696315 countsByYear W19636963152016 @default.
• W1963696315 countsByYear W19636963152017 @default.
• W1963696315 countsByYear W19636963152018 @default.
• W1963696315 countsByYear W19636963152019 @default.
• W1963696315 countsByYear W19636963152020 @default.
• W1963696315 countsByYear W19636963152021 @default.
• W1963696315 countsByYear W19636963152022 @default.
• W1963696315 countsByYear W19636963152023 @default.
• W1963696315 crossrefType "journal-article" @default.
• W1963696315 hasAuthorship W1963696315A5001683046 @default.
• W1963696315 hasAuthorship W1963696315A5005755753 @default.
• W1963696315 hasAuthorship W1963696315A5006271095 @default.
• W1963696315 hasAuthorship W1963696315A5023246606 @default.
• W1963696315 hasAuthorship W1963696315A5073470602 @default.
• W1963696315 hasAuthorship W1963696315A5075602116 @default.
• W1963696315 hasAuthorship W1963696315A5076901585 @default.
• W1963696315 hasAuthorship W1963696315A5088582143 @default.
• W1963696315 hasConcept C126322002 @default.
• W1963696315 hasConcept C134018914 @default.
• W1963696315 hasConcept C2775887513 @default.
• W1963696315 hasConcept C2777180221 @default.
• W1963696315 hasConcept C2777391703 @default.
• W1963696315 hasConcept C2779306644 @default.
• W1963696315 hasConcept C2779768347 @default.
• W1963696315 hasConcept C2781308992 @default.
• W1963696315 hasConcept C3018667095 @default.
• W1963696315 hasConcept C555293320 @default.
• W1963696315 hasConcept C71924100 @default.
• W1963696315 hasConcept C98274493 @default.
• W1963696315 hasConceptScore W1963696315C126322002 @default.
• W1963696315 hasConceptScore W1963696315C134018914 @default.
• W1963696315 hasConceptScore W1963696315C2775887513 @default.
• W1963696315 hasConceptScore W1963696315C2777180221 @default.
• W1963696315 hasConceptScore W1963696315C2777391703 @default.
• W1963696315 hasConceptScore W1963696315C2779306644 @default.
• W1963696315 hasConceptScore W1963696315C2779768347 @default.
• W1963696315 hasConceptScore W1963696315C2781308992 @default.
• W1963696315 hasConceptScore W1963696315C3018667095 @default.
• W1963696315 hasConceptScore W1963696315C555293320 @default.
• W1963696315 hasConceptScore W1963696315C71924100 @default.
• W1963696315 hasConceptScore W1963696315C98274493 @default.
• W1963696315 hasIssue "3" @default.
• W1963696315 hasLocation W19636963151 @default.
• W1963696315 hasLocation W19636963152 @default.
• W1963696315 hasOpenAccess W1963696315 @default.

• next